Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00175643
Status:
COMPLETED
Last Update Posted:
2006-05-09
First Post:
2005-09-11
Brief Title:
Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses
Sponsor:
University of British Columbia
Organization:
University of British Columbia
Study Overview
Official Title:
Open-Label Study to Assess Safety and Efficacy of Imiquimod 5 Cream Applied 3 Days Per Week in 1 or 2 Cycles for Treatment of Actinic Keratoses on the Head
Status:
COMPLETED
Status Verified Date:
2006-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
It is believed that imiquimod 5 cream has the potential to be an effective treatment for actinic keratoses The purpose of this study is to evaluate the duration of the effect of topical imiquimod 5 topical cream for the treatment of actinic keratoses
Detailed Description:
This study will assess the safety and efficacy of imiquimod 5 cream applied to actinic keratoses on the head to reduce the size of lesions The objective is to analyze the effect of dose cycling with respect to the complete clearance rate when imiquimod 5 cream is applied 3 times per week for 4 weeks in 1 or 2 cycles The complete clearance rate is defined as the proportion of subjects with no clinically visible AK lesions in the treatment area at the end of cycle 1 or the end of cycle 2
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None